etalocib
Small moleculeexperimental
Etalocib is a drug candidate that was under development for the treatment of various types of cancer. It acts as a leukotriene B4 receptor antagonist and a PPARγ agonist. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2000 (NCT00006375)
Timeline
Indications
Mechanism of action
PPARG agonist
- Leukotriene B4 receptor 1ANTAGONIST
LTB4R antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCc1c(OCCCOc2cc(O)c(-c3ccc(F)cc3)cc2CC)cccc1Oc1ccccc1C(=O)O- Mol. weight
- 544.62 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEtalocib ↗
- ChEMBLCHEMBL329123 ↗
Also known as
- 2-(2-propyl-3-(3-(2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy)propoxy)phenoxy)benzoic acid
- etalocib
- etalocib
- etalocib
- ly-193111
- ly-193111
- ly293111
- ly293111
- ly293111
- ly 293111
- ly-293111
- ly-293111
- ly-293111
- vml295
- vml-295
- vml-295
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00069875 | Phase 2 | Sep 1, 2003 | Eli Lilly |
| NCT00055250 | Phase 2 | Jan 1, 2003 | Eli Lilly |
| NCT00006375 | Phase 1 | Jun 1, 2000 | Cornell University, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 1 | 2003 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
3 organizations
Page 1 / 1